New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
CA 2134359 C · Owner: Pfizer Limited · Inventors: Hamanaka, Ernest S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I), the pharmaceutically acceptable salts thereof wherein Q, R17, R18 and R1 are as defined below. The compounds of formula (I) are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 20, 1993 and granted July 1, 1997. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 20, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 20, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.